Innoviva, Inc. INVA

INVA Company Overview

Innoviva, Inc. is a publicly traded healthcare royalty and therapeutics company focused on respiratory disease, infectious disease, and critical care assets. The company operates primarily through the acquisition and management of royalty interests, commercial pharmaceutical products, and strategic healthcare investments. Historically, Innoviva became known for its long-standing collaboration with GlaxoSmithKline (GSK) tied to respiratory therapies incorporating vilanterol, a long-acting beta agonist discovered by Innoviva. Royalty streams from products such as Breo Ellipta, Anoro Ellipta, and Trelegy Ellipta have historically represented a major source of cash flow.

Over time, Innoviva evolved from a biotechnology research company formerly known as Theravance, Inc. into a diversified healthcare holding and operating company. In addition to royalty-based income, the company expanded through acquisitions and investments in anti-infectives and hospital-focused pharmaceutical businesses. Its positioning is differentiated by its combination of durable respiratory royalty assets, ownership stakes in commercial-stage healthcare companies, and exposure to infectious disease therapies addressing antimicrobial resistance and critical care needs.